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Light-activated protein-conjugation and 89Zr-radiolabelling with 
water-soluble desferrioxamine derivatives 
 
Amaury Guillou,[a] Daniel F. Earley[a] and Jason P. Holland*[a] 
 
Abstract: Protein-conjugates are vital tools in biomedical research, 
drug discovery and imaging science. For example, functionalised 
monoclonal antibodies (mAbs) coupled to the desferrioxamine B 
(DFO) chelate and radiolabelled with 89Zr are used as 
radiopharmaceuticals for diagnostic positron emission tomography 
(PET). In this context, protein functionalisation requires the formation 
of a covalent bond which must be achieved without compromising the 
biological properties of the mAb. Photochemistry offers new synthetic 
routes toward protein-conjugates like 89Zr-mAbs but to harness the 
potential of light-induced conjugation reactions new photoactivatable 
reagents are required. Here, we introduce two photoactivatable DFO-
derivatives functionalised with an aryl azide (ArN3) for use in light-
activated conjugation and radiosynthesis of 89Zr-mAbs. Incorporation 
of a tris-polyethylene glycol (PEG)3 linker between DFO and the ArN3 
group furnished water-soluble chelates that were used in the one-pot, 
photoradiosynthesis of different 89Zr-radiolabelled protein-conjugates 
with radiochemical yields up to 72.9±1.9%. Notably, the DFO-PEG3 
chelates can be readily synthesised in accordance with Good 
Laboratory Practice (GLP), which will facilitate clinical trials with 
photoradiolabelled 89Zr-mAbs. 
Reagents that undergo photochemical activation are striking 
alternatives to the well-established thermochemically activated 
routes toward protein functionalisation.[1,2] The absorption of light 
by compounds containing benzophenone, diazirine or ArN3 
groups generates highly reactive diradical, carbene or nitrene 
intermediates, which under optimised conditions can form 
covalent bonds to protein. In a biologically compatible medium, 
these reactive intermediates exhibit lifetimes in the nanosecond 
(ns) to microsecond (µs) range. Such extreme reactivity is 
inaccessible from traditional thermochemically-mediated 
processes and mechanistically implies that if successful 
bimolecular protein-conjugation is to be achieved, the coupling 
step must kinetically outcompete other non-productive 
background reactions including hydrolysis, protonation or 
quenching by oxygen.[3–5] 
We recently demonstrated that metal ion binding chelates 
functionalised with a photoactivatable ArN3 group can be used to 
prepare radiolabelled antibodies by either a two-step conjugation 
and radiolabelling process or by a novel one-pot approach.[6–11] 
Simultaneous 89Zr-radiolabelling and light-induced conjugation 
using a photoactivatable DFO-ArN3 derivative produced viable 
PET radiotracers (Scheme 1).[7,11] Additionally, the photochemical 
conjugation process is compatible with standard formulation 
buffers, which allows direct synthesis of radiolabelled-mAbs from 
approved drugs like HerceptinTM. Experimentally, the efficiency 
and reproducibility of the photochemistry depends on several 
factors including the reaction geometry, light intensity, emission 
wavelength, and the stability and solubility of the reagents in basic 
conditions. 
Scheme 1. Illustration of the general concept of the one-pot, light-activated 
photoradiolabelling to produce 89Zr-mAbs. 
There have been many reports of alternative, octadentate 
chelates for selective radiolabelling of proteins with 89Zr4+ 
ions.[12,13] In the clinic, DFO remains the chelate of choice for PET 
imaging with 89Zr-mAbs. DFO is normally conjugated to mAbs via 
reactive groups such as activated esters or benzyl-
isothiocyanates that are introduced to the terminal primary amine 
of the chelate. A limitation is that functionalisation of the primary 
amine of DFO often compromises the water-solubility, and can 
lead to problems controlling the conjugation chemistry. 
Two approaches to circumvent solubility issues have been 
reported. Richardson-Sanchez et al. hijacked the biosynthetic 
machinery of Streptomyces pilosus to install ether groups into the 
backbone of the hexadentate DFO ligand, bioisosterically 
replacing the –(CH2)5– unit with a –(CH2)2O(CH2)2– moiety to give 
the water-soluble DFO-O3 ligand (Figure 1).[14] Similar methods 
were also used to introduce redox-active disulfide bonds.[15] In 
parallel, Briand et al. used solid-phase synthesis to produce the 
water-soluble, octadentate chelate oxoDFO* which incorporated 
four ether groups in the ligand backbone.[16] Computational 
studies revealed that the ether functionalities in DFO-O3 and 
oxoDFO* could potentially increase the thermodynamic stability 
of 89Zr4+ complexes by reducing ligand strain.[17] Although 
biosynthetic chemistry and solid-phase techniques are advanced 
routes to new chelates, and solubility characteristics were 
improved, these chemistries present challenges for making GLP-
compliant materials for use in clinical translation. Here, we report 
a simple approach to the synthesis of water-soluble DFO 
derivatives coupled to a photoactivatable ArN3 group via a 
polyethylene glycol (PEG)3 linker. 
[a] Dr A. Guillou, Dr D. F. Earley, Prof. Dr J. P. Holland* 
University of Zurich, Department of Chemistry, Winterthurerstrasse 
190, Zurich, CH-8057, Switzerland 
 E-mail: jason.holland@chem.uzh.ch  
 Tel: +41.44.63.53.990 
 Homepage: http://www.hollandlab.org   



















Chemistry - A European Journal
This article is protected by copyright. All rights reserved.





Figure 1. Chemical structures of DFO and four water-soluble DFO-derivatives. 
Compounds 4 and 9 are reported in this work.  
The functionalised DFO-PEG3-ArN3 (4; Scheme 2) and DFO-
PEG3-EtArN3 (9; supporting Scheme S1) metal binding chelates 
were synthesised by using standard chemical transformations 
with overall yields of 36% and 14%, respectively. Full 
experimental details and characterisation data, including 1H and 
13C{1H} NMR spectroscopy and high-resolution electrospray 
ionisation mass spectrometry for compounds 1 to 9, are provided 
in the supporting information (Figures S1–S37). The synthesis of 
compound 4 was achieved on a gram scale with simple isolation 
by reversed-phase C18 flash chromatography. 
Scheme 2. Multi-step synthesis of the water-soluble, photoactivatable chelate, 
DFO-PEG3-ArN3 (4). 
89Zr-radiolabelling reactions were performed at room 
temperature by adding aliquots of [89Zr][Zr(C2O4)4]4– (89Zr-oxalate) 
to samples of compounds 4 or 9 dissolved in water and adjusting 
to pH8.0–8.5 with Na2CO3 (the optimum range for our 
photoradiosynthesis).[6,7] 89Zr-radiolabelling was characterised by 
using radio-instant thin layer chromatography (radio-ITLC) and 
radio-HPLC methods (Figure 2). Quantitative 89Zr-radiolabelling 
yields were obtained in <5 min. The chemical identity and 
radiochemical purity (RCP) of the products were confirmed by 
comparison of the HPLC elution profiles to that of the 
corresponding non-radioactive natZr-complexes (Figure 2B; blue 
and green traces; Figure S37 for nat/89Zr-9+ data). Irradiation of the 
[89Zr]ZrDFO-PEG3-ArN3 (nat/89Zr-4+) samples with a powerful light-
emitting diode (LED) with peak emission at 395 nm confirmed the 
photochemical activity of the complex (Figure 2B, red trace). 
Complete photoactivation of nat/89Zr-4+ was observed in <15 min. 
Next, we evaluated the efficiency of compounds 4 and 9 in the 
photoradiosynthesis of a series of 89Zr-radiolabelled proteins. 
Formulated protein substrates included human serum albumin 
(HSA), the engineered antibody onartuzumab (formulated as 
MetMAbTM), and the humanised IgG1 immunoglobulin 
trastuzumab (formulated as HerceptinTM). Simultaneous (one-pot) 
photoradiolabelling reactions were performed in accordance with 
Scheme 3.[7,11] 
Figure 2. Radioactive chromatography showing: (A) radio-ITLC 
chromatograms of [89Zr]ZrDFO-PEG3-ArN3 before (blue) and after (red) 
photolysis at 395 nm. The elution profile of [89Zr][Zr(DTPA)]– (black) is shown as 
a control. (B) HPLC chromatograms shown the elution profile of compound 4 
(black trace), the nonradioactive natZr-complex (green), and the [89Zr]ZrDFO-
PEG3-ArN3 before (blue) and after (red) photolysis at 395 nm. 
Scheme 3. Simultaneous (one-pot) protein conjugation and 89Zr-radiolabelling 
of proteins using light-induced activation of DFO-PEG3-ArN3 (4). Successful 
protein radiolabelling was achieved with HSA (MW = 69.08 kDa), onartuzumab 
(99.16 kDa) and trastuzumab (MW ~150 kDa). 
Aliquots of the photoactivatable compounds 4 or 9 were mixed 
with the separate protein solutions in transparent glass vials, and 
then [89Zr][Zr(C2O4)4]4– was added to give final reaction volume of 
150 µL. Reaction mixtures were stirred gently and irradiated (395 
nm) for 15 min. at room temperature to ensure complete 
photoactivation. Aliquots of the crude reaction mixtures were 
retained for analysis and fractions were purified by preparative 
size-exclusion gel filtration (PD-10) methods. Crude and purified 
samples were analysed by radio-ITLC, analytical PD-10 size-
exclusion chromatography (SEC), and automated HPLC coupled 
to a SEC gel-filtration column (Figure 3 and supporting Figures 
S38–S41). 
After irradiation, isolated and decay-corrected (d.c.) 
radiochemical yields (RCYs) for the [89Zr]ZrDFO-PEG3-azepin-
protein reactions with compound 4 were 72.9±1.9% for HSA, 
64.5±6.7% for MetMAbTM, and 58.3±3.4% for HerceptinTM (n = 3 
independent measurements for each reaction; with final protein 
concentrations in the reaction mixtures of 175 µM, 141 µM, 77 µM, 
respectively). For comparison, reactions to form [89Zr]ZrDFO-
PEG3-azepin-HSA by irradiation at a shorter wavelength (365 nm) 
gave an average RCY of 70.7±2.3% (n = 3). For each reaction the 
radiochemical purity (RCP) of the isolated products was >90% 
(determined by HPLC). Protein aggregation was <5%, and when 
compared to the analysis of the protein stock solutions, did not 
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with compound 9 to form [89Zr]ZrDFO-PEG3-Et-azepin-HSA was 
also performed and gave an isolated d.c. RCY of 59.6±3.6% (n = 
3). Although both compounds 4 and 9 are water-soluble, the 
dissolution of compound 9 in water was improved by adding <1% 
DMSO/H2O. The addition of DMSO does not appear to interfere 
with the photoactivation or protein-conjugation steps. In contrast 
to our previous work with DFO-ArN3, the facile reactions and high 
reproducibility of these experiments likely stems from the 
enhanced water-solubility of compounds 4 and 9.[7] 
The slightly improved solubility profile of compound 4 
compared with compound 9 (which contains a more lipophilic 
ethylene group) led us to pursue further biological studies using 
[89Zr]ZrDFO-PEG3-azepin-onartuzumab. Chelate challenge 
experiments demonstrated that [89Zr]ZrDFO-PEG3-azepin-
onartuzumab remained stable with respect to changes in RCP 
during incubation with excess diethylenetriamine pentaacetate 
(DTPA; >50 mM, pH7, 37 oC, 94 h; supporting Figure S42). After 
incubation for 4 days, <16% of the radioactivity was found to 
transchelate to DTPA to give [89Zr][Zr(DTPA)]– which is consistent 
with the excellent stability of the ZrDFO complex under 
physiological conditions.[18] Saturation binding experiments were 
also performed by incubating [89Zr]ZrDFO-PEG3-azepin-
onartuzumab with human gastric carcinoma MKN-45 cells 
(supporting Figure S43). These cellular studies revealed that 
[89Zr]ZrDFO-PEG3-azepin-onartuzumab was immunoreactive and 
displayed specific binding to the human hepatocyte growth-factor 
receptor (c-MET).[19] 
Encouraged by the experimental results in vitro, we pursued 
small-animal PET imaging and biodistribution experiments in 
female athymic nude mice bearing subcutaneous MKN-45 human 
xenografts on the right shoulder (Figure 4; maximum intensity 
project [MIP] images are given in supporting Figure S44). The 
photoradiosynthesis of [89Zr]ZrDFO-PEG3-azepin-onartuzumab 
was scaled up and the isolated product was formulated in sterile 
PBS (pH7.4). Two groups of animals (n = 5 mice/group) received 
between 0.46–0.60 MBq of 89Zr radioactivity. The first group 
received a normal dose containing a total mass of 59–72 µg of 
onartuzumab per animal while the same 
activity dose but an increased protein 
mass (823–834 µg of onartuzumab per 
animal) were administered to the control 
(blocking) group to modulate the tumour 
uptake by saturating the available c-MET 
receptors. Quantitative volume-of-interest 
(VOI) analysis from the PET images 
revealed high accumulation of 89Zr-
radioactivity in the tumours of the normal 
group reaching 14.3±1.7 %ID cm-3 (n = 5) 
by 72 h post-administration (supporting 
Figure S45). In comparison, radiotracer 
uptake in tumours of the blocking group 
showed a statistically significant decrease 
of over 40% and reached only 
8.5±0.9 %ID cm-3 (n = 5) after 72 h 
(Student’s t-test P-value < 0.001). These 
data confirmed that [89Zr]ZrDFO-PEG3-
azepin-onartuzumab remained 
immunoreactive and displayed specific binding to the c-MET 
receptor in vivo. 
Figure 4. Coronal and axial PET images taken through the centre of the 
tumours showing the spatial distribution of [89Zr]ZrDFO-PEG3-azepin-
onartuzumab over time after intravenous administration in mice bearing MKN-
45 tumours. T = tumour, H = heart, L = liver, K = kidney. 
As additional controls, PET images were also recorded at 
multiple time points (0 – 16 h post-administration) in mice that 
received [89Zr]ZrDFO-PEG3-ArN3 (Figure S46; synthesised in the 
dark) or a photolysed sample of [89Zr]ZrDFO-PEG3-azepin that 
was irradiated at 395 nm for 15 min. at room temperature in the 
absence of protein (Figure S47). VOI analysis (supporting Figure 
S48 and Table S1) revealed that [89Zr]ZrDFO-PEG3-ArN3 or the 
photolysed byproducts have dramatically different 
pharmacokinetic profiles when compared with [89Zr]ZrDFO-PEG3-
azepin-onartuzumab. [89Zr]ZrDFO-PEG3-ArN3 and photolysed 
[89Zr]ZrDFO-PEG3-azepin were cleared rapidly from the 
circulation as demonstrated by the absence of 89Zr-activity in the 
heart/blood pool. Both samples showed unusually high uptake in 
the gall bladder with rapid elimination of 89Zr-activity observed via 
both intestinal and renal pathways. By 2 h post-administration, 
89Zr-activity in the bladder and kidneys was almost entirely 
cleared whereas activity in the abdominal region migrated from 
the small to the large intestine. These PET data indicate that 
purification of our photoradiolabelled proteins by preparative size-
exclusion small-molecule effectively removed all small-molecule 
contaminants since no uptake in the gall bladder or intestines was 
Figure 3. Radioactive chromatography showing: (A) radio-ITLC chromatograms of purified (blue) 
[89Zr]ZrDFO-PEG3-azepin-onartuzumab (MetMAbTM). (B) Analytical SEC (PD-10) elution profiles showing 
the crude (black) and purified (blue) samples of [89Zr]ZrDFO-PEG3-azepin-onartuzumab. (C) Radioactive 
and electronic absorption HPLC chromatograms acquired using SEC gel-filtration showing analysis of the 
crude (black) and purified (blue) samples. Note (*) corresponds to a protein aggregate fraction; (D) 
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observed in the PET images recorded with [89Zr]ZrDFO-PEG3-
azepin-onartuzumab. 
Biodistribution studies were performed at 72 h on all animals 
after the final imaging time point (Figure 5; supporting Figures 
S49–S51 and Table S2). Ex vivo analysis corroborated the PET 
data and confirmed the specific tumour uptake and low retention 
of [89Zr]ZrDFO-PEG3-azepin-onartuzumab in background tissues.  
Figure 5. Bar chart showing ex vivo biodistribution data (%ID g-1) for the uptake 
of [89Zr]ZrDFO-PEG3-azepin-onartuzumab in the (normal group, white; blocking 
group, blue) in mice bearing MKN-45 tumours. 
Our experimental studies confirmed that photoradiosynthesis 
of 89Zr-radiolabelled proteins with water-soluble DFO-derivatives 
produces viable PET radiotracers. However, proteins contain 
different nucleophiles that could attack the ketenimine 
intermediate produced by photoactivation of ArN3 groups. To 
investigate the reaction coordinate for the light-induced activation 
of ArN3 and to probe the potential reactivity of different 
nucleophiles, we used density functional theory (DFT; supporting 
Scheme S2, Table S3 and Figures S52–S55) calculations. 
intramolecular rearrangement and bimolecular reactions with 
AcO– (modelling Glu / Asp residues) nucleophiles. Computational 
results indicated that nucleophilic attack by MeNH2 (modelling Lys 
residues) at the ketenimine formed by photoactivation of 
compound 4 has a free energy barrier of +51.3 kJ mol-1. In 
contrast, a significantly higher barrier of +62.8 kJ mol-1 was 
obtained with AcO– as the incoming nucleophile (modelling Glu / 
Asp residues). Differences in the kinetic barriers (labelled as TS4 
in Table S3) suggest that lysine residues are more likely to react 
than Glu/Asp carboxylate groups. Notably, extensive DFT studies 
were unable to find appropriate transition states for the attack of 
H2O, HO–, MeOH, MeO–, MeSH, MeS– nucleophiles at the 
ketenimine intermediates indicating that reactions with cysteine, 
threonine or serine residues are unlikely to occur by this 
mechanism. Further experiments are required to confirm the 
proposed chemoselectivity of light-induced protein-conjugation 
using photoactivatable ArN3 compounds. 
In conclusion, accessing water-soluble DFO-derivatives 
bearing discrete (PEG)3 linkers is simple and facilitates the use of 
photochemistry in the synthesis of 89Zr-mAbs. Further studies are 
underway to evaluate the impact of the PEG unit on the metabolic 
stability of protein-conjugates in vivo. Compound 4 has been 
produced in accordance with GLP regulations which will expedite 
the synthesis of clinical-grade 89Zr-mAbs by photoradiosynthesis. 
Experimental Section 
Full experimental details and characterisation data are provided 
in the Supporting Information. 
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